Document Classification

Section Type: RESULTS

Text: At weeks 24 and 48 of treatment and 24 after treatment end, group A showed significantly higher (vs. group B, P < 0. 05) rates of reduced HBV DNA viral loads (81. 8 %, 90. 9 %, and 75. 8 % vs. 53. 1 %, 56. 2 %, and 59. 4 %), VR (48. 5 %, 60. 6 %, and 42. 4 % vs. 31. 3 %, 34. 4 %, and 31. 3 %), HBeAg-negativity (39. 4 %, 60. 6 %, and 54. 5 % vs. 12. 5 %, 37. 5 %, and 37. 5 %), HBeAg seroconversion (27. 3 %, 54. 5 %, and 48. 5 % vs. 6. 3 %, 15. 6 %, and 18. 8 %), and ALT normalization (72. 7 %, 84. 8 %, and 78. 8 % vs. 46. 9 %, 56. 3 %, and 46. 9 %).